No Data
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating
Annexon Is Maintained at Overweight by Wells Fargo
Annexon Is Maintained at Overweight by Wells Fargo
Express News | Wells Fargo Maintains Overweight on Annexon, Lowers Price Target to $10
Express News | Annexon Inc : JP Morgan Cuts Target Price to $11 From $13
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Annexon Biosciences (ANNX) and Ascendis Pharma (ASND)
HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $30 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.